
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5757870/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. New England Journal of Medicine, 2020, 382, 2158-2160.	27.0	976
2	SEXDIFFERENCES INPHARMACOKINETICS ANDPHARMACODYNAMICS. Annual Review of Pharmacology and Toxicology, 2004, 44, 499-523.	9.4	438
3	Facial Masking for Covid-19 — Potential for "Variolation―as We Await a Vaccine. New England Journal of Medicine, 2020, 383, e101.	27.0	182
4	Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer. Journal of General Internal Medicine, 2020, 35, 3063-3066.	2.6	180
5	Does Patient Sex Affect Human Immunodeficiency Virus Levels?. Clinical Infectious Diseases, 2002, 35, 313-322.	5.8	156
6	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Reports, 2021, 36, 109518.	6.4	142
7	Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). PLoS ONE, 2014, 9, e83736.	2.5	125
8	Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7795-E7804.	7.1	121
9	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Science Advances, 2021, 7, .	10.3	117
10	Atazanavir Concentration in Hair Is the Strongest Predictor of Outcomes on Antiretroviral Therapy. Clinical Infectious Diseases, 2011, 52, 1267-1275.	5.8	116
11	Low Lopinavir Plasma or Hair Concentrations Explain Second-Line Protease Inhibitor Failures in a Resource-Limited Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 333-339.	2.1	101
12	SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. Lancet HIV,the, 2021, 8, e334-e341.	4.7	99
13	Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the Latinx Population During Shelter-in-Place in San Francisco. Clinical Infectious Diseases, 2021, 73, S127-S135.	5.8	94
14	Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study. Lancet HIV,the, 2020, 7, e249-e261.	4.7	94
15	Poverty, unstable housing, and HIV infection among women living in the United States. Current HIV/AIDS Reports, 2007, 4, 181-186.	3.1	92
16	Protease inhibitor levels in hair strongly predict virologic response to treatment. Aids, 2009, 23, 471-478.	2.2	92
17	Sensitive analysis of antiâ€HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 3401-3409.	1.5	83
18	Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. Current HIV/AIDS Reports, 2020, 17, 301-314.	3.1	83

#	Article	IF	CITATIONS
19	Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. Clinical Infectious Diseases, 2018, 66, 213-219.	5.8	82
20	Loneliness in Older Adults Living with HIV. AIDS and Behavior, 2018, 22, 1475-1484.	2.7	82
21	Antiretroviral Concentrations in Small Hair Samples as a Feasible Marker of Adherence in Rural Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 311-315.	2.1	80
22	Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. Aids, 2005, 19, 1885-1896.	2.2	79
23	Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19. Aids, 2020, 34, 2328-2331.	2.2	76
24	A Pharmacist‣ed Program to Evaluate and Reduce Polypharmacy and Potentially Inappropriate Prescribing in Older <scp>HIV</scp> â€Positive Patients. Pharmacotherapy, 2017, 37, 1498-1506.	2.6	73
25	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. Journal of Infectious Diseases, 2019, 219, 1084-1094.	4.0	73
26	Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 13-20.	2.1	72
27	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV,the, 2016, 3, e521-e528.	4.7	66
28	Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, e104-e106.	2.1	64
29	HIV pre-exposure prophylaxis for women. Journal of Virus Eradication, 2016, 2, 149-155.	0.5	63
30	Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. Journal of Infectious Diseases, 2015, 212, 1402-1406.	4.0	62
31	Common clinical conditions – age, low BMI, ritonavir use, mild renal impairment – affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. Aids, 2014, 28, 59-66.	2.2	61
32	A mentor training program improves mentoring competency for researchers working with early-career investigators from underrepresented backgrounds. Advances in Health Sciences Education, 2015, 20, 683-689.	3.3	61
33	A Single-Nucleotide Polymorphism in CYP2B6 Leads to >3-Fold Increases in Efavirenz Concentrations in Plasma and Hair Among HIV-Infected Women. Journal of Infectious Diseases, 2012, 206, 1453-1461.	4.0	59
34	Drug Overdose Deaths Before and After Shelter-in-Place Orders During the COVID-19 Pandemic in San Francisco. JAMA Network Open, 2021, 4, e2110452.	5.9	59
35	Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity. Lancet Infectious Diseases, The, 2021, 21, e296-e301.	9.1	57
36	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infectious Diseases, 2022, 9, ofab640.	0.9	56

#	Article	IF	CITATIONS
37	Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. Aids, 2015, 29, 825-830.	2.2	53
38	Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Research and Human Retroviruses, 2017, 33, 778-783.	1.1	52
39	Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value. AIDS and Behavior, 2018, 22, 1165-1173.	2.7	51
40	COVID-19 Susceptibility and Outcomes Among People Living With HIV in San Francisco. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 19-21.	2.1	51
41	Evaluation of a novel community-based COVID-19 †̃Test-to-Care' model for low-income populations. PLoS ONE, 2020, 15, e0239400.	2.5	51
42	Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 72-77.	2.1	50
43	Creating More Effective Mentors: Mentoring the Mentor. AIDS and Behavior, 2016, 20, 294-303.	2.7	49
44	Missed Visits Associated With Future Preexposure Prophylaxis (PrEP) Discontinuation Among PrEP Users in a Municipal Primary Care Health Network. Open Forum Infectious Diseases, 2019, 6, ofz101.	0.9	49
45	Randomized controlled trial of a positive affect intervention to reduce HIV viral load among sexual minority men who use methamphetamine. Journal of the International AIDS Society, 2019, 22, e25436.	3.0	49
46	Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. Aids, 2017, 31, 2245-2251.	2.2	47
47	Using the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol. BMC Public Health, 2017, 17, 383.	2.9	46
48	Hair and Plasma Data Show That Lopinavir, Ritonavir, and Efavirenz All Transfer From Mother to Infant In Utero, But Only Efavirenz Transfers via Breastfeeding. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 578-584.	2.1	45
49	Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. Aids, 2015, 29, 183-191.	2.2	45
50	Hair It Is: The Long and Short of Monitoring Antiretroviral Treatment. Annals of Internal Medicine, 2002, 137, 696.	3.9	44
51	Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV,the, 2019, 6, e43-e50.	4.7	43
52	Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients. PLoS ONE, 2015, 10, e0129100.	2.5	43
53	Seroconversion on preexposure prophylaxis. Aids, 2018, 32, F1-F4.	2.2	42
54	Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence. EClinicalMedicine, 2018, 2-3, 22-28.	7.1	42

#	Article	IF	CITATIONS
55	Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study. Clinical Infectious Diseases, 2022, 75, e916-e919.	5.8	42
56	Short Communication: A Low-Cost Method for Analyzing Nevirapine Levels in Hair as a Marker of Adherence in Resource-Limited Settings. AIDS Research and Human Retroviruses, 2014, 30, 25-28.	1.1	41
57	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, e127-e134.	2.1	41
58	Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 327-332.	1.2	41
59	Degree of Housing Instability Shows Independent "Dose-Response―With Virologic Suppression Rates Among People Living With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2018, 5, ofy035.	0.9	41
60	Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in tororo, uganda. Journal of Clinical Pharmacology, 2014, 54, 121-132.	2.0	40
61	Movement between facilities for HIV care among a mobile population in Kenya: transfer, loss to follow-up, and reengagement. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1386-1393.	1.2	40
62	Missed opportunities to prevent HIV infections among preâ€exposure prophylaxis users: a populationâ€based mixed methods study, San Francisco, United States. Journal of the International AIDS Society, 2020, 23, e25472.	3.0	40
63	"The Pleasure Is Better as l've Gotten Older― Sexual Health, Sexuality, and Sexual Risk Behaviors Among Older Women Living With HIV. Archives of Sexual Behavior, 2017, 46, 1137-1150.	1.9	38
64	Gendered dimensions of population mobility associated with HIV across three epidemics in rural Eastern Africa. Health and Place, 2019, 57, 339-351.	3.3	38
65	Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings. Aids, 2020, 34, 255-260.	2.2	38
66	Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. Aids, 2013, 27, 2413-2423.	2.2	37
67	Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2011, 401, 1923-1933.	3.7	36
68	Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis. Clinical Infectious Diseases, 2018, 67, 962-964.	5.8	35
69	HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. PLoS Medicine, 2021, 18, e1003492.	8.4	35
70	HIV and women in the USA: what we know and where to go from here. Lancet, The, 2021, 397, 1107-1115.	13.7	35
71	Smoking Cessation and Recidivism in the Women's Interagency Human Immunodeficiency Virus Study. American Journal of Preventive Medicine, 2014, 47, 53-69.	3.0	33
72	Implementation challenges for long-acting antivirals as treatment. Current Opinion in HIV and AIDS, 2015, 10, 282-289.	3.8	33

#	Article	IF	CITATIONS
73	Behavioral Intervention Improves Treatment Outcomes Among HIV-Infected Individuals Who Have Delayed, Declined, or Discontinued Antiretroviral Therapy: A Randomized Controlled Trial of a Novel Intervention. AIDS and Behavior, 2015, 19, 1801-1817.	2.7	33
74	Population mobility associated with higher risk sexual behaviour in eastern African communities participating in a Universal Testing and Treatment trial. Journal of the International AIDS Society, 2018, 21, e25115.	3.0	33
75	HIV pre-exposure prophylaxis for women. Journal of Virus Eradication, 2016, 2, 149-55.	0.5	33
76	Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children. AIDS Research and Human Retroviruses, 2015, 31, 1009-1014.	1.1	32
77	Brief Report: A Panel Management and Patient Navigation Intervention Is Associated With Earlier PrEP Initiation in a Safety-Net Primary Care Health System. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 347-351.	2.1	31
78	Uniting Infectious Disease and Physical Science Principles on the Importance of Face Masks for COVID-19. Med, 2021, 2, 29-32.	4.4	30
79	Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here. BMC Public Health, 2021, 21, 2084.	2.9	30
80	COVID-19 Vaccine Hesitancy Among PLWH in South India: Implications for Vaccination Campaigns. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 421-425.	2.1	29
81	Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project. Aids, 2019, 33, 867-872.	2.2	29
82	The Effect of a "Universal Antiretroviral Therapy" Recommendation on HIV RNA Levels Among HIV-Infected Patients Entering Care With a CD4 Count Greater Than 500/ÂL in a Public Health Setting. Clinical Infectious Diseases, 2012, 55, 1690-1697.	5.8	28
83	Development and Implementation of a Workshop to Enhance the Effectiveness of Mentors Working with Diverse Mentees in HIV Research. AIDS Research and Human Retroviruses, 2014, 30, 730-737.	1.1	28
84	Patient and provider perceptions of a comprehensive care program for HIV-positive adults over 50 years of age: The formation of the Golden Compass HIV and aging care program in San Francisco. PLoS ONE, 2018, 13, e0208486.	2.5	26
85	"Wan Kanyakla―(We are together): Community transformations in Kenya following a social network intervention for HIV care. Social Science and Medicine, 2015, 147, 332-340.	3.8	25
86	Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania. Aids, 2018, 32, 1115-1123.	2.2	25
87	Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 55-59.	2.1	24
88	Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study). Clinical Infectious Diseases, 2020, 70, 2143-2151.	5.8	24
89	Mentoring the Mentors: Implementation and Evaluation of Four Fogarty-Sponsored Mentoring Training Workshops in Low-and Middle-Income Countries. American Journal of Tropical Medicine and Hygiene, 2019, 100, 20-28.	1.4	24
90	Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 295-298.	2.1	23

#	Article	IF	CITATIONS
91	Nonnucleoside Reverse Transcriptase Inhibitor Pharmacokinetics in a Large Unselected Cohort of HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 482-491.	2.1	22
92	Addressing the Sexually Transmitted Infection and HIV Syndemic. JAMA - Journal of the American Medical Association, 2019, 321, 1356.	7.4	22
93	Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. Clinical Infectious Diseases, 2019, 68, 1044-1047.	5.8	22
94	Coronavirus Disease 2019 (COVID-19) and HIV Spotlight the United States Imperative for Permanent Affordable Housing. Clinical Infectious Diseases, 2021, 72, 2042-2043.	5.8	22
95	Moving Antiretroviral Adherence Assessments to the Modern Era: Correlations Among Three Novel Measures of Adherence. AIDS and Behavior, 2020, 24, 284-290.	2.7	21
96	Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 169-174.	2.1	20
97	Human papillomavirus knowledge, vaccine acceptance, and vaccine series completion among female entertainment and sex workers in Phnom Penh, Cambodia: the Young Women's Health Study. International Journal of STD and AIDS, 2015, 26, 893-902.	1.1	19
98	Brief Report: Lopinavir Hair Concentrations Are the Strongest Predictor of Viremia in HIV-Infected Asian Children and Adolescents on Second-Line Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 367-371.	2.1	19
99	Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention. Current HIV/AIDS Reports, 2020, 17, 487-498.	3.1	19
100	A Simple Pre-Exposure Prophylaxis (PrEP) Optimization Intervention for Health Care Providers Prescribing PrEP: Pilot Study. JMIR Formative Research, 2018, 2, e2.	1.4	19
101	Viral suppression during COVID-19 among people with HIV experiencing homelessness in a low-barrier clinic-based program. Aids, 2021, 35, 517-519.	2.2	19
102	Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. PLoS ONE, 2018, 13, e0190118.	2.5	18
103	Measuring Adherence to Antiretroviral Therapy via Hair Concentrations in India. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 202-206.	2.1	18
104	Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 78-82.	2.1	18
105	Increase of perceived frequency of neighborhood domestic violence is associated with increase of women's depression symptoms in a nationally representative longitudinal study in South Africa. Social Science and Medicine, 2015, 131, 89-97.	3.8	17
106	Housing Instability Results in Increased Acute Care Utilization in an Urban HIV Clinic Cohort. Open Forum Infectious Diseases, 2019, 6, ofz148.	0.9	17
107	The Time for Universal Masking of the Public for Coronavirus Disease 2019 Is Now. Open Forum Infectious Diseases, 2020, 7, ofaa131.	0.9	17
108	Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. Journal of Infectious Diseases, 2018, 218, 234-238.	4.0	16

#	Article	IF	CITATIONS
109	Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 158-162.	2.1	16
110	Motivational Interviewing to Reduce Drug Use and HIV Incidence Among Young Men Who Have Sex With Men in Relationships and Are High Priority for Pre-Exposure Prophylaxis (Project PARTNER): Randomized Controlled Trial Protocol. JMIR Research Protocols, 2019, 8, e13015.	1.0	16
111	Predicting death over 8 years in a prospective cohort of HIV-infected women: the Women's Interagency HIV Study. BMJ Open, 2017, 7, e013993.	1.9	15
112	Strong Correlation Between Concentrations of Antiretrovirals in Home-Collected and Study-Collected Hair Samples: Implications for Adherence Monitoring. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, e101-e103.	2.1	15
113	Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative Approach. Clinical Infectious Diseases, 2021, 72, 1843-1849.	5.8	15
114	Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis. PLoS ONE, 2016, 11, e0155887.	2.5	15
115	Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine. Aids, 2018, 32, 2189-2194.	2.2	14
116	Feasibility and acceptability of novel methods to estimate antiretroviral adherence: A longitudinal study. PLoS ONE, 2019, 14, e0210791.	2.5	14
117	The Golden Compass Program: Overview of the Initial Implementation of a Comprehensive Program for Older Adults Living with HIV. Journal of the International Association of Providers of AIDS Care, 2020, 19, 232595822093526.	1.5	14
118	Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e15029.	1.0	14
119	Patient and clinician perspectives on optimizing graphical displays of longitudinal medication adherence data. Patient Education and Counseling, 2019, 102, 1090-1097.	2.2	13
120	Brief Report: Understanding Preferences for HIV Care Among Patients Experiencing Homelessness or Unstable Housing: A Discrete Choice Experiment. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 444-449.	2.1	13
121	Evaluation of the POP-UP programme: a multicomponent model of care for people living with HIV with homelessness or unstable housing. Aids, 2021, 35, 1241-1246.	2.2	13
122	Acceptability and Feasibility of Self-Collecting Biological Specimens for HIV, Sexually Transmitted Infection, and Adherence Testing Among High-Risk Populations (Project Caboodle!): Protocol for an Exploratory Mixed-Methods Study. JMIR Research Protocols, 2019, 8, e13647.	1.0	13
123	Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS Research and Human Retroviruses, 2022, 38, 455-462.	1.1	13
124	Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 149-158.	2.1	12
125	HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health. Aids, 2020, 34, 699-706.	2.2	12
126	Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection. Clinical Infectious Diseases, 2021, 72, 486-489.	5.8	12

#	Article	IF	CITATIONS
127	Pilot Randomized Controlled Trial of Motivational Interviewing with Sexual Minority Male Couples to Reduce Drug Use and Sexual Risk: The Couples Health Project. AIDS and Behavior, 2022, 26, 310-327.	2.7	12
128	Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2018, 32, 431-441.	1.5	11
129	Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women. Aids, 2019, 33, 1657-1662.	2.2	11
130	Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 149-152.	2.1	11
131	Social Support Mitigates Negative Impact of Food Insecurity on Antiretroviral Adherence Among Postpartum Women in Western Kenya. AIDS and Behavior, 2020, 24, 2885-2894.	2.7	11
132	Human herpesvirus 8, Kaposi's sarcoma, and associated conditions. Clinics in Laboratory Medicine, 2002, 22, 883-910.	1.4	10
133	Novel methods to estimate antiretroviral adherence: protocol for a longitudinal study. Patient Preference and Adherence, 2018, Volume 12, 1033-1042.	1.8	10
134	Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. International Journal of Infectious Diseases, 2020, 97, 365-370.	3.3	10
135	Distinct forms of migration and mobility are differentially associated with HIV treatment adherence. Aids, 2022, 36, 1021-1030.	2.2	10
136	HIV Treatment Outcomes in POP-UP: Drop-in HIV Primary Care Model for People Experiencing Homelessness. Journal of Infectious Diseases, 2022, 226, S353-S362.	4.0	10
137	The Effect of AIDS Clinical Trials Group Protocol 5164 on the Time From Pneumocystis jirovecii Pneumonia Diagnosis to Antiretroviral Initiation in Routine Clinical Practice: A Case Study of Diffusion, Dissemination, and Implementation. Clinical Infectious Diseases, 2011, 53, 1008-1014.	5.8	9
138	An LC-MS/MS-based method to analyze the anti-tuberculosis drug bedaquiline in hair. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1069-1070.	1.2	9
139	Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validated LC-MS/MS panel. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1125, 121729.	2.3	9
140	Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB. ERJ Open Research, 2019, 5, 00046-2019.	2.6	9
141	Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis. Open Forum Infectious Diseases, 2019, 6, ofz463.	0.9	9
142	Evaluating the Impact of Housing Status on Gonorrhea and Chlamydia Screening in an HIV Primary Care Setting. Sexually Transmitted Diseases, 2019, 46, 153-158.	1.7	9
143	Improving Care Outcomes for PLWH Experiencing Homelessness and Unstable Housing: a Synthetic Review of Clinic-Based Strategies. Current HIV/AIDS Reports, 2020, 17, 259-267.	3.1	9
144	Tenofovir-based PrEP for COVID-19: an untapped opportunity?. Aids, 2021, 35, 1509-1511.	2.2	9

#	Article	IF	CITATIONS
145	A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. Journal of Antimicrobial Chemotherapy, 2021, 76, 1865-1873.	3.0	9
146	Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing. Open Forum Infectious Diseases, 2021, 8, ofab200.	0.9	9
147	Characterizing the COVID-19 Illness Experience to Inform the Study of Post-acute Sequelae and Recovery. International Journal of Behavioral Medicine, 2022, 29, 610-623.	1.7	9
148	Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis. PLoS ONE, 2017, 12, e0189101.	2.5	8
149	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. AIDS Research and Human Retroviruses, 2019, 35, 788-793.	1.1	8
150	A mentor training workshop focused on fostering diversity engenders lasting impact on mentoring techniques: Results of a long-term evaluation. Journal of Clinical and Translational Science, 2021, 5, e116.	0.6	8
151	COVID-19 Mitigation With Appropriate Safety Measures in an Essential Workplace: Lessons for Opening Work Settings in the United States During COVID-19. Open Forum Infectious Diseases, 2021, 8, ofab086.	0.9	8
152	Examining the Impact of the Golden Compass Clinical Care Program for Older People with HIV: A Qualitative Study. AIDS and Behavior, 2022, 26, 1562-1571.	2.7	8
153	Willingness to Donate Hair Samples for Research Among People Living with HIV/AIDS Attending a Tertiary Health Facility in Ibadan, Nigeria. AIDS Research and Human Retroviruses, 2019, 35, 642-648.	1.1	7
154	Pragmatic randomized trial of a pre-visit intervention to improve the quality of telemedicine visits for vulnerable patients living with HIV. Journal of Telemedicine and Telecare, 2023, 29, 187-195.	2.7	7
155	The Drinkers' Intervention to Prevent Tuberculosis (DIPT) trial among heavy drinkers living with HIV in Uganda: study protocol of a 2×2 factorial trial. Trials, 2021, 22, 355.	1.6	7
156	Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes. BMJ Open, 2021, 11, e050116.	1.9	7
157	Equity in access to long-acting injectables in the USA. Lancet HIV,the, 2022, 9, e145-e147.	4.7	7
158	A multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs. International Journal of Tuberculosis and Lung Disease, 2016, 20, 991-992.	1.2	6
159	Individual and partnership factors associated with anticipated versus actual partner notification following STI diagnosis among men who have sex with men and/or with transgender women in Lima, Peru. Sexually Transmitted Infections, 2018, 94, 607-610.	1.9	6
160	PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men. AIDS and Behavior, 2021, 25, 1299-1305.	2.7	6
161	Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. Aids, 2021, 35, 1919-1927.	2.2	6
162	Short Communication: Higher Tenofovir Concentrations in Hair Are Associated with Decreases in Viral Load and Not Self-Reported Adherence in HIV-Infected Adolescents with Second-Line Virological Treatment Failure. AIDS Research and Human Retroviruses, 2021, 37, 748-750.	1.1	5

#	Article	IF	CITATIONS
163	Point-of-Care Test for Assessing Tenofovir Adherence: Feasibility and Recommendations from Women in an Oral PrEP Program in Kenya and Their Healthcare Providers. AIDS and Behavior, 2021, 25, 3617-3629.	2.7	5
164	Adjudicating Reasons for Hospitalization Reveals That Severe Illness From COVID-19 in Children Is Rare. Hospital Pediatrics, 2021, 11, e159-e160.	1.3	5
165	Preferences for Conditional Economic Incentives to Improve Pre-exposure Prophylaxis Adherence: A Discrete Choice Experiment Among Male Sex Workers in Mexico. AIDS and Behavior, 2022, 26, 833-842.	2.7	5
166	The impact of COVID-19 on mentoring early-career investigators. Medicine (United States), 2021, 100, e27423.	1.0	5
167	Geriatric conditions and healthcare utilisation in older adults living with HIV. Age and Ageing, 2022, 51, .	1.6	5
168	A COVID-19 conference at AIDS 2020: Virtual. Lancet, The, 2020, 395, 1598-1599.	13.7	4
169	The importance of PrEP persistence in preventing HIV infections on PrEP. Journal of the International AIDS Society, 2020, 23, e25578.	3.0	4
170	Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis. Clinical Infectious Diseases, 2021, 72, 2025-2028.	5.8	4
171	Masks Reduce Viral Inoculum of SARS-CoV2. Journal of General Internal Medicine, 2021, 36, 1124-1125.	2.6	4
172	Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamideâ€based ART. Drug Testing and Analysis, 2021, 13, 1354-1370.	2.6	4
173	Machine Learning Algorithms Using Routinely Collected Data Do Not Adequately Predict Viremia to Inform Targeted Services in Postpartum Women Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 439-447.	2.1	4
174	Impact of Multicomponent Support Strategies on Human Immunodeficiency Virus Virologic Suppression Rates During Coronavirus Disease 2019: An Interrupted Time Series Analysis. Clinical Infectious Diseases, 2022, 75, e947-e954.	5.8	4
175	Brief Report: Heterogeneous Preferences for Care Engagement Among People With HIV Experiencing Homelessness or Unstable Housing During the COVID-19 Pandemic. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 140-145.	2.1	4
176	Determinants of Viral Resuppression or Persistent Virologic Failure After Initial Failure With Second-Line Antiretroviral Treatment Among Asian Children and Adolescents With HIV. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 253-256.	1.3	3
177	Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1169, 122467.	2.3	3
178	Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting. BMC Infectious Diseases, 2021, 21, 99.	2.9	3
179	Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 57-60.	2.1	3
180	A qualitative assessment of barriers and facilitators to antiretroviral adherence in Thai patients. Journal of Virus Eradication, 2016, 2, 22-7.	0.5	3

#	Article	IF	CITATIONS
181	1298. Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report. Open Forum Infectious Diseases, 2018, 5, S396-S397.	0.9	2
182	Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	2
183	Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings. Aids, 2021, 35, 1439-1449.	2.2	2
184	Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases – Authors' reply. Lancet Infectious Diseases, The, 2021, 21, 915-916.	9.1	2
185	High Acceptability of Donating Hair and Other Biological Samples for Research Among People Living with HIV in an Outpatient Clinic in Lagos, Nigeria. AIDS Research and Human Retroviruses, 2021, 37, 676-682.	1.1	2
186	Brief Report: Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 181-185.	2.1	2
187	Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples. Journal of Visualized Experiments, 2020, , .	0.3	2
188	Immunity Against the Omicron Variant From Vaccination, Recovery, or Both. Clinical Infectious Diseases, 2022, 75, e672-e674.	5.8	2
189	Relationship Dynamics are Associated with Self-Reported Adherence but not an Objective Adherence Measure in Malawi. AIDS and Behavior, 2022, 26, 3551-3562.	2.7	2
190	An Incidental Abscess in a Patient With Acquired Immunodeficiency Syndrome. Infectious Diseases in Clinical Practice, 2012, 20, 405-406.	0.3	1
191	Extent of In Utero Transfer of Tenofovir From Mother to Fetus: A Paired Analysis of Hair Specimens Collected at Birth From a Cohort in the United States. Journal of Infectious Diseases, 2021, 223, 638-644.	4.0	1
192	Disparities in Integrase Inhibitor Usage in the Modern HIV Treatment Era: A Population-Based Study in a US City. Open Forum Infectious Diseases, 2021, 8, ofab139.	0.9	1
193	Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria. AIDS Research and Therapy, 2022, 19, .	1.7	1
194	2272. High Interest in Doxycycline for Sexually Transmitted Infection Post-Exposure Prophylaxis (Doxy-PEP) in a Multi-city Survey of Men Having Sex With Men (MSM) Using a Social-Networking App. Open Forum Infectious Diseases, 2018, 5, S672-S673.	0.9	0
195	Detectable HIV RNA in late pregnancy associated with low tenofovir hair levels at time of delivery among women living with HIV in the United States. Aids, 2021, 35, 267-274.	2.2	0
196	Effectiveness of Adding a Mask Recommendation to Other Public Health Measures. Annals of Internal Medicine, 2021, 174, 1193-1193.	3.9	0